Background & aim: Translational models are essential to identify improved treatment options for chronic kidney disease (CKD) patients. However, most preclinical CKD models do not demonstrate reduced glomerular filtration rate (GFR) or improvement by standard of care (SoC). The aim…
Background & aim: Bulk RNA-sequencing has limited cellular-level insight into metabolic-associated steatohepatitis (MASH) and its progression to hepatocellular carcinoma (HCC) by masking rare and tumor-relevant populations. Here, we used single-cell transcriptomics to characterize liver cell-specific transcriptomic changes in the GAN…
Background & aim: Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and holds great promise as therapeutic target for metabolic dysfunctionassociated steatohepatitis (MASH). Efruxifermin (EFX) is a long acting FGF21 analogue currently in phase 3…
Background & aim: The long-acting glucagon-like peptide-1 (GLP1) receptor agonist semaglutide was recently approved as the first GLP-1–based therapy for people with MASH and moderate-to-severe fibrosis. Clinical studies have demonstrated that semaglutide not only improves liver histology but also reverses…
Background & aim: Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as promising therapeutic candidates for metabolic dysfunction-associated steatohepatitis (MASH). Importantly, semaglutide was recently approved as the first GLP-1-based treatment for people with MASH with moderate-to-severe fibrosis. Translational models that recapitulate…
Background & aim: Growing evidence suggests that senescent cells contribute to the development and progression of idiopathic pulmonary fibrosis (IPF). The present study aimed to evaluate molecular signatures of pulmonary senescence in the single and repetitive bleomycin (BLEO)-induced and spirometry-confirmed…
Background & aim: Effective treatment of muscle diseases requires comprehensive, multidimensional assessment of muscle structure, mass, and function. This need is particularly evident in sarcopenia, where age-related loss of muscle mass and quality drives functional decline, increased morbidity, and frailty…
Background & aim: Glucagon influences kidney function through both direct intrarenal glucagon receptor (GCGR) signaling and indirect humoral pathways. Increasing evidence suggests that renal GCGR activity is impaired in chronic kidney disease (CKD). Survodutide is a novel, long-acting dual GCGR/GLP-1…
Background & aim: Long-acting amylin analogues offer mechanistic complementarity to incretin-based therapies for obesity. Accordingly, CagriSema, a fixed-dose combination of the amylin analogue Cagrilintide and the GLP-1 analogue Semaglutide, has demonstrated superior weight loss compared with either agent alone in recent clinical trials…
Background & aim: Classification and counting of ovarian follicles is a key endpoint in preclinical models of reproductive disorders. Traditionally, this relies on manual histopathological scoring subjecting to inter- and intra-observer variability, thus affecting reproducibility. This study aimed to validate GHOST (Gubra…